![Daniel Wainstein](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Daniel Wainstein
Presidente presso STELLA DIAGNOSTICS INC.
Patrimonio netto: 555 $ in data 31/05/2024
Posizioni attive di Daniel Wainstein
Società | Posizione | Inizio | Fine |
---|---|---|---|
STELLA DIAGNOSTICS INC. | Presidente | - | - |
CHAIN BRIDGE I | Presidente | 01/01/2024 | - |
Seven Knots LLC | Corporate Officer/Principal | - | - |
Storia della carriera di Daniel Wainstein
Precedenti posizioni note di Daniel Wainstein
Società | Posizione | Inizio | Fine |
---|---|---|---|
Varian Biopharmaceuticals, Inc.
![]() Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Direttore/Membro del Consiglio | - | - |
JMD Properties, Inc.
![]() JMD Properties, Inc. Medical SpecialtiesHealth Technology JMD Properties, Inc. is a content conversion service provider, developer, and integrator for the 3D Stereo and auto-stereo media industry. Its services include proprietary 3D reality splitter 2D to 3D conversion; stereo and multi-view consulting and integration; value added reseller of turnkey multi-view systems for digital signage. The company was founded in 1989 and is headquartered in Cheyenne, WY. | Amministratore Delegato | - | - |
Formazione di Daniel Wainstein
Hofstra University | Undergraduate Degree |
Maurice A. Deane School of Law at Hofstra University | Graduate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
2 |
Posizioni
Chairman | 2 |
Undergraduate Degree | 1 |
Graduate Degree | 1 |
Settori
Health Technology | 4 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
CHAIN BRIDGE I | Finance |
STELLA DIAGNOSTICS INC. | Health Technology |
Aziende private | 3 |
---|---|
JMD Properties, Inc.
![]() JMD Properties, Inc. Medical SpecialtiesHealth Technology JMD Properties, Inc. is a content conversion service provider, developer, and integrator for the 3D Stereo and auto-stereo media industry. Its services include proprietary 3D reality splitter 2D to 3D conversion; stereo and multi-view consulting and integration; value added reseller of turnkey multi-view systems for digital signage. The company was founded in 1989 and is headquartered in Cheyenne, WY. | Health Technology |
Seven Knots LLC | |
Varian Biopharmaceuticals, Inc.
![]() Varian Biopharmaceuticals, Inc. BiotechnologyHealth Technology Part of Healthtech Solutions, Inc., Varian Biopharmaceuticals, Inc. is a private precision oncology company based in Naples, FL. Varian Bio is developing novel therapeutics for the treatment of cancer using precision oncology, which involves DNA testing to identify genetic mutations in tumors for more targeted treatment recommendations. Varian Bio's lead drug candidate, Var-101, is being developed in a topical formulation for the treatment of basal cell carcinoma, while Var-102, an oral formulation, is being developed for the treatment of various solid tumors, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer. Varian Bio is also seeking additional precision oncology therapeutic candidates for its pipeline and exploring development collaborations. The CEO of the company is Jeffrey Blaine Davis. Varian Biopharmaceuticals was acquired by Healthtech Solutions, Inc. on May 07, 2021. | Health Technology |
- Borsa valori
- Insiders
- Daniel Wainstein
- Esperienza